Global Oncology Liquid Biopsy (LBx) Market Report, Fourth Edition: 2026 - 2031

Technologies and Revenues Included:

• Liquid biopsies, in which a bodily fluid, primarily blood, is taken to detect molecular biomarkers
• Any soluble analyte (e.g., cfDNA, cfRNA, CTCs, exosomes, methylation)
• LBx testing done in routine clinical care and as part of biopharma trials and translational research
• Oncology-focused applications including cancer early detection (EDx), therapy (Tx) selection, and minimum residual disease (MRD) / monitoring
• Kits / reagents (e.g., off the shelf assays and LBx library prep) used in the testing of blood-based oncology biomarkers; the revenue captured is there venue to the kit manufacturer
• Send-out services in which a sample is sent to a centralized testing location; the revenue captured is the revenue to the service provider

Technologies and Revenues Excluded:

• Germline testing, prognostic testing, or any other kind of testing performed on analytes extracted from peripheral blood cells
• Academic trials and research (i.e., non-industry sponsored)
• Applications outside of solid tumor oncology such as organ transplant, reproductive health, prenatal screening, routine bloodwork
• Sequencing reagents used to perform the assay
• Instruments and platforms used to run / analyze LBx samples (e.g., NGS, PCR machines)
• Software or bioinformatics support used in the analysis of LBx assays
• CDx licensing and development deals revenue, even if the licensing / deal involved LBx

‍

Updated Content

• Incorporated the latest trends in the LBx market, based on interviews (N = 34) with experts and extensive secondary research
• Assessed new / current offerings and expected future portfolio developments
• Provided verbatim quotes from primary research to illustrate a variety of viewpoints and experiences
• Updated our database of liquid biopsy companies and their offerings, evaluated the latest performance data from key players
• Updated market sizing, segmentation, and forecast based on primary research findings and publicly-available financials
• Evaluated emerging, high-growth applications in depth, elucidating both quantitative and qualitative market divers, moderators, and trends: (Minimal residual disease / monitoring, Early cancer detection)
• Updated and added new deep-dive profiles of select key competitors

‍

Updated Market Numbers

• Updated four market models to estimate the different segments of the LBx market; triangulated the market estimates against publicly available data(e.g., from SEC filings)
• Informed model assumptions with primary and secondary research, as well as DeciBio domain expertise
• Assessed market sizes for each of the market segments analyzed, including:
  • Customer type (clinical, pharma)
  • Indication
  • Application
  • Competitor
  • Geography
• Projected revenues for each market segment from current year (2026) through 2031

‍

‍

• Introduction & Methodology
• Executive Summary
• Therapy Selection
• MRD / Monitoring
• Early Cancer Detection
• Biopharma Trials & Research
• Company Profiles
• Primary Vendor Feedback (Available as part of the Global license only)
• Appendix

‍